Oral booster probiotic bifidobacteria in SARS-COV-2 patients

Basit Öğe Kaydı
dc.authorid0000-0001-7198-8421en_US
dc.authorscopusid57225898564en_US
dc.contributor.authorBozkurt H.S.
dc.contributor.authorBilen, Ömer
dc.date.accessioned2022-01-27T06:27:52Z
dc.date.available2022-01-27T06:27:52Z
dc.date.issued2021en_US
dc.departmentBTÜ, Mimarlık ve Tasarım Fakültesi, Şehir ve Bölge Planlama Bölümüen_US
dc.description.abstractOral booster-single strain probiotic bifidobacteria could be a potential strategy for SARS-CoV-2. This study aims to evaluate the role of oral probiotic Bifidobacterium on moderate/severe SARS-CoV-2 inpatients. In this single-center study, we analyzed data of 44 moderate/severe inpatients with diagnosed COVID-19 in Istanbul Maltepe University Medical Faculty Hospital, 2020 from 1 November 2020 to 15 December 2020. Clinical and medication features were compared and analyzed between patients with or without probiotic. In result, 19 of the 44 patients (43.18%) who were administrated with oral booster-single strain probiotic were discharged with the median inpatient day of 7.6 days which were significantly shorter than those of patients without probiotic. There were significant differences in inpatient days, radiological improvement at day 6 and week 3, and reduction in interleukin-6 levels in those receiving oral probiotic therapy. Although the mortality rate was 5% in the probiotic group, it was 25% in the non-probiotic group. Booster-single strain probiotic bifidobacteria could be an effective treatment strategy for moderate/severe SARS-CoV-2 inpatients to reduce the mortality and length of stay in hospital.en_US
dc.identifier.doi10.1177/20587384211059677en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://hdl.handle.net/20.500.12885/1812
dc.identifier.volume35en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorBilen, Ömer
dc.language.isoenen_US
dc.publisherSAGE Publications Inc.en_US
dc.relation.ispartofInternational Journal of Immunopathology and Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbifidobacteriaen_US
dc.subjectprobioticen_US
dc.subjectSARS-CoV-2en_US
dc.titleOral booster probiotic bifidobacteria in SARS-COV-2 patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
20587384211059677.pdf
Boyut:
684.09 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Şehir ve Bölge Planlama Bölümü Yayın Koleksiyonu